Gastroenterology
Volume 129, Issue 3 , Pages 837-845, September 2005

Evaluation of a Large, Population-Based Sample Supports a CpG Island Methylator Phenotype in Colon Cancer

  • Wade S. Samowitz

      Affiliations

    • Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah
    • Corresponding Author InformationAddress requests for reprints to: Wade S. Samowitz, MD, Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah 84132. fax: (801) 585-3831.
  • ,
  • Hans Albertsen

      Affiliations

    • Health Research Center, Department of Family and Preventive Medicine, Salt Lake City, Utah
  • ,
  • Jennifer Herrick

      Affiliations

    • Health Research Center, Department of Family and Preventive Medicine, Salt Lake City, Utah
  • ,
  • Theodore R. Levin

      Affiliations

    • Kaiser Permanente Medical Center, Walnut Creek, California
  • ,
  • Carol Sweeney

      Affiliations

    • Health Research Center, Department of Family and Preventive Medicine, Salt Lake City, Utah
  • ,
  • Maureen A. Murtaugh

      Affiliations

    • Health Research Center, Department of Family and Preventive Medicine, Salt Lake City, Utah
  • ,
  • Roger K. Wolff

      Affiliations

    • Health Research Center, Department of Family and Preventive Medicine, Salt Lake City, Utah
  • ,
  • Martha L. Slattery

      Affiliations

    • Health Research Center, Department of Family and Preventive Medicine, Salt Lake City, Utah

Received 21 January 2005; accepted 26 May 2005.

Background & Aims: The concept of a CpG island methylator phenotype (CIMP), especially in microsatellite stable colon cancer, is not accepted universally. We therefore evaluated a large population-based sample of individuals with colon cancer and used univariate and multivariate analyses of CIMP with clinicopathologic variables and tumor mutations to determine the biologic relevance of this phenotype. Methods: A total of 864 tumors from individuals with colon cancer from Utah and Northern California were evaluated by methylation-specific polymerase chain reaction of CpG islands in hMLH1, methylated in tumors (MINT) 1, MINT 2, MINT 31, and CDKN2A (p16). CIMP high was defined as methylation at 2 or more of these loci. The BRAF V600E mutation was determined by sequencing. Microsatellite instability had been determined previously. Results: In a multivariate analysis of microsatellite stable tumors, CIMP high was related significantly to the V600E BRAF mutation (odds ratio, 39.52; 95% confidence interval, 11.44–136.56), KRAS2 mutations (odds ratio, 2.22; 95% confidence interval, 1.48–3.34), older age (P trend = .03), and increased stage (P trend = .03), and these tumors were less likely to be located in the distal colon (odds ratio, .42; 95% confidence interval, .27–.65). CIMP-high unstable tumors also were more likely to have the V600E BRAF mutation, be located proximally, and occur in older individuals (in univariate analyses). However, CIMP-high unstable tumors were significantly more likely than their stable counterparts to be KRAS2 wild type, TP53 wild type, poorly differentiated, proximally located, occur at lower stages, and have the BRAF V600E mutation (64.1% vs 17.6%). Conclusions: The evaluation of a large, population-based sample strongly supports the biologic relevance of CIMP in colon cancer. However, the presence or absence of microsatellite instability has a major effect on the expression of this phenotype.

Abbreviations used in this paper:  AJCC, American Joint Committee on Cancer , CI, confidence interval , CIMP, CpG island methylator phenotype , HNPCC, hereditary nonpolyposis colon cancer , MINT, methylated in tumors , OR, odds ratio , TGF-β RII, transforming growth factor β receptor type II

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official view of the National Cancer Institute.Supported by grants CA48998 and CA61757 (to M.L.S.), and by the Utah Cancer Registry, which is funded by contract N01-PC-67000 from the National Cancer Institute, with additional support from the State of Utah Department of Health, the University of Utah, the Northern California Cancer Registry, and the Sacramento Tumor Registry.

PII: S0016-5085(05)01122-4

doi:10.1053/j.gastro.2005.06.020

Refers to article:

  • CIMP, at Last

    Jean-Pierre J. Issa, Lanlan Shen, Minoru Toyota
    Gastroenterology September 2005 (Vol. 129, Issue 3, Pages 1121-1124)

Gastroenterology
Volume 129, Issue 3 , Pages 837-845, September 2005